Clinical trial NCT00721695: Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.
Official title: Randomized, Controlled, Double-Masked, Multicenter, Exploratory Study of the Clinical Benefit and Safety of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) Using a Coaxial Phacoemulsification Process
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cataract Extraction
Keywords: Cataract
Cataract Extraction
Lens Implantation
Phacoemulsification
Lead sponsor: Omeros Corporation
Sponsor class: INDUSTRY
First posted: 2008-07-24
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.

Detailed description: OMS302 Injection is a mydriatic/anti-inflammatory combination investigational drug product being developed as an irrigation solution during intracameral lens replacement surgical procedures of the eye. OMS302 irrigation solution may induce and maintain an adequately dilated pupil and reduce postoperative symptoms of discomfort such as eye pain and irritation. The use of OMS302 irrigation solution may eliminate the need for pre-operative dilation of the eye and could reduce the postoperative use of an anti-inflammatory and pain medications following surgery.

Eligibility criteria: Inclusion Criteria:

* Subject is 50 years of age or older.
* Subject is to undergo unilateral primary CELR for an age-related cataract under topical anesthesia and using a clear cornea incision.
* Subject's history and physical examination are within normal limits or the examination is clinically non-significant for purposes of the study as determined by the Investigator, and subject is in good general health.
* Subject has best corrected visual acuity (BCVA) of 20/400 or better in the non-study eye.
* Subject has intraocular pressure (IOP) between 5 mmHg and 22 mmHg, inclusive, in the study eye.

Exclusion Criteria:

* Subject is allergic to any of the individual ingredients in OMS302
* Subject who is taking medications with the same activities as that of the active ingredients in OMS302 for defined time intervals prior to and after surgery.
* Female subject of childbearing potential (i.e., not surgically sterilized nor post-menopausal longer than one year) who is not using an effective method of birth control within at least 14 days prior to surgery or has a positive pregnancy test.
* Subject who has a present condition or history of any clinically significant uncontrolled gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, connective tissue, respiratory, or medical disorder as determined by the Investigator.
* Subject who is taking anticoagulants.
* Subject who is taking or needs to take for the duration of the study any of the prohibited medications.
* Subject with pseudo-capsular exfoliation, or evidence of prior iritis or of ocular trauma with iris damage, or who has used pilocarpine within six months of screening.
* Subject that has uncontrolled chronic ocular disease.
* Subject that has active corneal pathology or scarring noted in either eye (except superficial punctate keratopathy in the non-study eye).
* Subject that has extraocular/intraocular inflammation in either eye.
* Subject has an active bacterial and/or viral infection in either eye.
* Subject that has narrow-angle glaucoma, unstable glaucoma, or glaucoma being treated with prostaglandins or prostaglandin analogues.
* Subject taking, or has taken within the past year, an alpha adrenergic antagonist.
* Subject that has participated in or is currently participating in any investigational drug or device trial within the previous 30 days prior to the day of surgery.
* Subject that has had intraocular conventional surgery within the past three months or intraocular laser surgery within one month of the planned surgery in the study eye.
* Subject that requires the use of other topical medications during the trial except prophylactic antibiotics, topical lid care or glaucoma medications or tear replacement solutions.
* Subject that needs other ocular surgery at the time of the cataract extraction.

Primary outcomes:
measure: Pupil diameter
timeFrame: Day of Surgery
measure: Pain and other measures of ocular discomfort
timeFrame: 14 days
measure: Degree of inflammation in the anterior chamber
timeFrame: 14 days
Secondary outcomes:
measure: Ocular safety and changes in visual activity and intraocular pressure
timeFrame: 28 days
measure: General measures of safety
timeFrame: 28 days
Other outcomes:
Locations:
city: Redding
country: United States
facility: Shasta Eye Medical Group
state: California
city: Bloomington
country: United States
facility: Chu Vision Institute
state: Minnesota
city: Kansas City
country: United States
facility: Silverstein Eye Centers
state: Missouri
city: Madison
country: United States
facility: Davis Duehr Dean
state: Wisconsin
Study officials:
affiliation: Omeros Corporation
name: Scott Houston
role: STUDY_DIRECTOR
References:
citation: Behndig A, Eriksson A. Evaluation of surgical performance with intracameral mydriatics in phacoemulsification surgery. Acta Ophthalmol Scand. 2004 Apr;82(2):144-7. doi: 10.1111/j.1600-0420.2004.00241.x.
citation: Lundberg B, Behndig A. Intracameral mydriatics in phacoemulsification cataract surgery. J Cataract Refract Surg. 2003 Dec;29(12):2366-71. doi: 10.1016/s0886-3350(03)00522-4.